
Now in its second year and with an expanded curriculum, HCV Care & Guidance: Practical Education and Resources continues to guide your staff in the optimal use of new direct-acting antiviral (DAA) therapies in treating your patients with chronic hepatitis C virus (HCV) infection.
In May 2011, the FDA approved two new drugs for the treatment of chronic hepatitis C infection: boceprevir and telaprevir. These drugs, when combined with peginterferon and ribavirin, offer a new standard of care with significantly higher response rates and shorter durations of therapy compared with PEG IFN/RBV, giving new hope to HCV-infected patients.
A free online and point-of-care program, HCV Care & Guidance includes 16 separate activities and numerous practical resources that are designed to deliver an integrated learning experience covering the clinical issues related to DAA therapy.
In May 2011, the FDA approved two new drugs for the treatment of chronic hepatitis C infection: boceprevir and telaprevir. These drugs, when combined with peginterferon and ribavirin, offer a new standard of care with significantly higher response rates and shorter durations of therapy compared with PEG IFN/RBV, giving new hope to HCV-infected patients.
A free online and point-of-care program, HCV Care & Guidance includes 16 separate activities and numerous practical resources that are designed to deliver an integrated learning experience covering the clinical issues related to DAA therapy.